Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Eloxx Pharmaceuticals, Inc. | elox-ex322_9.htm |
| EX-32.1 - EX-32.1 - Eloxx Pharmaceuticals, Inc. | elox-ex321_14.htm |
| EX-31.2 - EX-31.2 - Eloxx Pharmaceuticals, Inc. | elox-ex312_13.htm |
| EX-31.1 - EX-31.1 - Eloxx Pharmaceuticals, Inc. | elox-ex311_6.htm |
| EX-21.1 - EX-21.1 - Eloxx Pharmaceuticals, Inc. | elox-ex211_10.htm |
| 10-K - 10-K - Eloxx Pharmaceuticals, Inc. | elox-10k_20201231.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-228430 and 333-224207 on Form S-3 and Registration Statement Nos. 333-236952, 333-224860, 333-222499, and 333-201891 on Form S-8 of our report dated March 12, 2021 relating to the consolidated financial statements of Eloxx Pharmaceuticals, Inc., appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 12, 2021